FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007267070> ?p ?o ?g. }

• W2007267070 endingPage "1106" @default.
• W2007267070 startingPage "S" @default.
• W2007267070 abstract "S A T A b st ra ct s examine the relationship between pre-treatment CEA and pCR in a large validated, population-based cohort. Methods: Patients with clinical stage II and III rectal cancer who underwent neoadjuvant chemoradiation and surgical resection with curative intent were selected from the 2006-2011 National Cancer Data Base. CEA was defined as normal, borderline and elevated based on the standards of each facility laboratory. Bivariate analysis was used to examine pCR rates across patient, tumor, and facility characteristics. Separate logistic regression models were used to estimate the odds of pCR, pathological tumor regression and tumor downsizing associated with normal, borderline, and elevated CEA levels after controlling for pertinent covariates. Results: Of 11,029 patients meeting inclusion criteria, 44% had elevated CEA and 12% experienced pCR. On bivariate analysis, elevated CEA was associated with decreased odds of pCR (OR=0.47, 95%CI=0.42-0.54, p<0.001). After adjusting for covariates, patients with an elevated CEA had a 50% decrease in the odds of pCR as compared to those with normal CEA (OR=0.50, 95%CI=0.44-0.58, p<0.001). Additionally, elevated CEA was associated with reduced pathological tumor regression (OR= 0.63, 95%CI=0.54-0.73, p<0.001) and reduced tumor downsizing (OR=0.55, 95%CI=0.510.60, p<0.001). There was no observed effect of borderline CEA on pCR (Table 1), tumor regression or tumor downsizing.Conclusion: Rectal cancer patients with an elevated pretreatment CEA are less likely to experience pCR, pathological tumor regression and tumor downsizing after neoadjuvant treatment. This may reflect unfavorable tumor biology or decreased responsiveness to treatment. These patients are very unlikely to achieve a significant tumor response following neoadjuvant therapy and are probably not suitable for a watch and wait strategy. These patients would most likely benefit from prompt surgical resection and expeditious delivery of adjuvant therapy rather than an extended duration between completion of neoadjuvant treatment and surgery as the likelihood of a significant tumor response is quite low." @default.
• W2007267070 created "2016-06-24" @default.
• W2007267070 creator A5013488451 @default.
• W2007267070 creator A5022134651 @default.
• W2007267070 creator A5029760021 @default.
• W2007267070 creator A5052416398 @default.
• W2007267070 creator A5059089028 @default.
• W2007267070 creator A5074465312 @default.
• W2007267070 creator A5076908226 @default.
• W2007267070 creator A5077141651 @default.
• W2007267070 creator A5085569847 @default.
• W2007267070 creator A5088154323 @default.
• W2007267070 date "2015-04-01" @default.
• W2007267070 modified "2023-09-25" @default.
• W2007267070 title "437 A Novel Immunocompetent Orthotopic Mouse Model of Pancreatic Cancer With Robust Stroma: A Unique Tool for Evaluation of Therapies" @default.
• W2007267070 doi "https://doi.org/10.1016/s0016-5085(15)33767-7" @default.
• W2007267070 hasPublicationYear "2015" @default.
• W2007267070 type Work @default.
• W2007267070 sameAs 2007267070 @default.
• W2007267070 citedByCount "0" @default.
• W2007267070 crossrefType "journal-article" @default.
• W2007267070 hasAuthorship W2007267070A5013488451 @default.
• W2007267070 hasAuthorship W2007267070A5022134651 @default.
• W2007267070 hasAuthorship W2007267070A5029760021 @default.
• W2007267070 hasAuthorship W2007267070A5052416398 @default.
• W2007267070 hasAuthorship W2007267070A5059089028 @default.
• W2007267070 hasAuthorship W2007267070A5074465312 @default.
• W2007267070 hasAuthorship W2007267070A5076908226 @default.
• W2007267070 hasAuthorship W2007267070A5077141651 @default.
• W2007267070 hasAuthorship W2007267070A5085569847 @default.
• W2007267070 hasAuthorship W2007267070A5088154323 @default.
• W2007267070 hasConcept C121608353 @default.
• W2007267070 hasConcept C126322002 @default.
• W2007267070 hasConcept C142724271 @default.
• W2007267070 hasConcept C204232928 @default.
• W2007267070 hasConcept C2780210213 @default.
• W2007267070 hasConcept C502942594 @default.
• W2007267070 hasConcept C52124034 @default.
• W2007267070 hasConcept C71924100 @default.
• W2007267070 hasConceptScore W2007267070C121608353 @default.
• W2007267070 hasConceptScore W2007267070C126322002 @default.
• W2007267070 hasConceptScore W2007267070C142724271 @default.
• W2007267070 hasConceptScore W2007267070C204232928 @default.
• W2007267070 hasConceptScore W2007267070C2780210213 @default.
• W2007267070 hasConceptScore W2007267070C502942594 @default.
• W2007267070 hasConceptScore W2007267070C52124034 @default.
• W2007267070 hasConceptScore W2007267070C71924100 @default.
• W2007267070 hasIssue "4" @default.
• W2007267070 hasLocation W20072670701 @default.
• W2007267070 hasOpenAccess W2007267070 @default.
• W2007267070 hasPrimaryLocation W20072670701 @default.
• W2007267070 hasRelatedWork W2005812634 @default.
• W2007267070 hasRelatedWork W2043890160 @default.
• W2007267070 hasRelatedWork W2084177191 @default.
• W2007267070 hasRelatedWork W2220916195 @default.
• W2007267070 hasRelatedWork W247384491 @default.
• W2007267070 hasRelatedWork W2600123923 @default.
• W2007267070 hasRelatedWork W2764038087 @default.
• W2007267070 hasRelatedWork W2810246221 @default.
• W2007267070 hasRelatedWork W2919252815 @default.
• W2007267070 hasRelatedWork W3013358603 @default.
• W2007267070 hasVolume "148" @default.
• W2007267070 isParatext "false" @default.
• W2007267070 isRetracted "false" @default.
• W2007267070 magId "2007267070" @default.
• W2007267070 workType "article" @default.